Press Releases

MOLOGEN has presented preclinical data on its EnanDIM technology at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in San Diego, United States. EnanDIM represents a new generation of the company’s immunoactivating TLR-9...

Two posters on clinical trials with the cancer immune therapy MGN1703 and one with the therapeutic cancer vaccine MGN1601 of the biotechnology company MOLOGEN AG have been accepted at the ESMO Congress in Madrid (September 26 – 30, 2014). Updated...

MOLOGEN AG has enrolled the first patient in the international IMPALA study. Primary objective of the phase III pivotal trial is to prove that a switch maintenance therapy with the cancer immunotherapy MGN1703 leads to an increased overall...

At the Annual General Meeting of MOLOGEN AG on August 13, 2014, the shareholders voted with a large majority in favour of the proposals of the Management and Supervisory Board in all agenda items. Essentially, it has been decided to create a new...

The first half of 2014 of MOLOGEN AG was characterized by expanded research and development activities. In particular, the clinical development program for cancer immunotherapy MGN1703 in the indications of colorectal cancer and lung cancer was...

MOLOGEN AG, a biotechnology company focused on cancer immunotherapy, has received first approvals from the countries participating in the phase III pivotal trial IMPALA. The company expects the first patient in the study (FPI) in the third quarter...

Two posters about the cancer immune therapy MGN1703 of the biotechnology company MOLOGEN AG have been presented at the ESMO 16th World Congress on Gastrointestinal Cancer (WCGI) in Barcelona. In the first one data on four patients in...